Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01820065
Other study ID # 05-003
Secondary ID
Status Completed
Phase N/A
First received March 25, 2013
Last updated March 27, 2013
Start date June 2005
Est. completion date October 2011

Study information

Verified date March 2013
Source Iladevi Cataract and IOL Research Center
Contact n/a
Is FDA regulated No
Health authority India: Data Monitoring Committee
Study type Observational

Clinical Trial Summary

Although contemporary cataract surgery has made tremendous strides in technological advancement, posterior capsular opacification (PCO) is still the most frequent long-term complication leading to decreased visual functions and thereby dissatisfying results. A great deal of effort has been made to develop new ways to prevent the formation of PCO. A key factor, widely discussed in literature, is the material and design of the intraocular lense (IOL) edge that can lead to PCO prevention. It is still not clear whether the sharp-edged IOL produces less PCO because of its optic geometry alone or whether the biomaterial contributes to the inhibition of PCO. With the clinical introduction of the single‐piece acrylic hydrophobic IOLs with some optic and haptic design differences compared with three‐piece acrylic hydrophobic IOLs, it has become possible to determine the influence of IOL material and design on PCO prevention. It is well established that the development of PCO is a dynamic process and that a longer follow-up time is correlated with a higher degree of PCO. So far, there have been prospective clinical studies on the clinical results of single and three‐piece acrylic hydrophobic foldable IOLs. However, the question as to as to whether the PCO further increases or becomes stable or regresses on a long-term basis has not yet been answered. Since there is paucity of available literature that prospectively evaluates the development of PCO with the implantation of the single-piece SN60AT hydrophobic acrylic IOL on a long-term basis, the investigators decided to observe the degree of development of PCO at 5 years after cataract surgery.


Recruitment information / eligibility

Status Completed
Enrollment 390
Est. completion date October 2011
Est. primary completion date October 2011
Accepts healthy volunteers No
Gender Both
Age group 40 Years to 75 Years
Eligibility Inclusion Criteria:

- patients with uncomplicated age-related cataract who were otherwise healthy

Exclusion Criteria:

- a history of diabetes mellitus (DM),

- patients with glaucoma,

- high myopia (axial length > 27.0 mm),

- pseudoexfoliation,

- traumatic cataract,

- subluxated cataract,

- previous ocular surgeries, and

- allergy to dilating drops.

Study Design

Observational Model: Cohort, Time Perspective: Prospective


Related Conditions & MeSH terms


Intervention

Procedure:
Cataract surgery with IOL implantation
Phacoemulsification with implantation of single piece Acrysof IOL

Locations

Country Name City State
India Iladevi Cataract & IOL Research Centre Ahmedabad Gujarat

Sponsors (1)

Lead Sponsor Collaborator
Iladevi Cataract and IOL Research Center

Country where clinical trial is conducted

India, 

Outcome

Type Measure Description Time frame Safety issue
Other Change in PCO at different followup intervals Change in PCO observed from 1 month to 1 year, 1 year to 3 years, and 3 years to 5 years upto 5 years postoperatively No
Primary Posterior Capsule Opacification Evaluation of PCO (EPCO) scores in the area of the intraocular lens (IOL) optic and in the central 3mm zone at 5 years after surgery 5 years followup No
Secondary EPCO Score and EPCO area with total on and part on anterior capsulorhexis cover over optic 5 years postoperatively No